Inactive Instrument

Analyst Reco. Five Prime Therapeutics, Inc.

Equities

FIVE PRIME THERAPEUTICS : Guggenheim Downgrades Five Prime Therapeutics to Neutral from Buy, Lifts PT to $38 From $29	21-03-09	MT
FIVE PRIME THERAPEUTICS : Jefferies Downgrades Five Prime Therapeutics to Hold From Buy; Price Target is $38	21-03-05	MT
FIVE PRIME THERAPEUTICS : Wells Fargo Downgrades Five Prime Therapeutics to Equal-Weight Rating From Overweight, Adjusts Price Target to $38 From $34	21-03-04	MT
FIVE PRIME THERAPEUTICS : Wedbush Cuts Five Prime Therapeutics to Neutral From Outperform on Pending Acquisition, Adjusts PT to $38 From $28	21-03-04	MT
FIVE PRIME THERAPEUTICS : SVB Leerink Adjusts Five Prime Therapeutics PT to $33 From $9, Maintains Outperform Rating	20-11-11	MT
FIVE PRIME THERAPEUTICS : Wedbush Adjusts PT on Five Prime Therapeutics to $28 From $9 on 'Knockout' Bemarituzumab Data; Outperform Rating Kept	20-11-11	MT
FIVE PRIME THERAPEUTICS : JPMorgan Upgrades Five Prime Therapeutics to Neutral From Underweight; Price Target is $14	20-11-11	MT
FIVE PRIME THERAPEUTICS : Wells Fargo Upgrades Five Prime Therapeutics to Overweight From Equal Weight; Price Target is $34	20-11-11	MT
FIVE PRIME THERAPEUTICS : SVB Leerink Adjusts Five Prime Therapeutics' Price Target to $9 From $11, Keeps at Outperform	20-11-04	MT

No results for this search